Sandbox:ap: Difference between revisions
Jump to navigation
Jump to search
Line 98: | Line 98: | ||
* ''↑ Phosphate'' | * ''↑ Phosphate'' | ||
|- | |- | ||
| rowspan="4" style="background: #F0FFFF; text-align: center;" |'''Malignancy''' | | rowspan="4" style="background: #F0FFFF; text-align: center;" |'''Malignancy'''<ref name="pmid26713296">{{cite journal |vauthors=Mirrakhimov AE |title=Hypercalcemia of Malignancy: An Update on Pathogenesis and Management |journal=N Am J Med Sci |volume=7 |issue=11 |pages=483–93 |year=2015 |pmid=26713296 |pmc=4683803 |doi=10.4103/1947-2714.170600 |url=}}</ref> | ||
| style="background: #F0FFFF; text-align: center;" |Humoral hypercalcemia of malignancy | | style="background: #F0FFFF; text-align: center;" |Humoral hypercalcemia of malignancy<ref name="pmid1346019">{{cite journal |vauthors=Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG |title=Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia |journal=Lancet |volume=339 |issue=8786 |pages=164–7 |year=1992 |pmid=1346019 |doi=10.1016/0140-6736(92)90220-W |url=}}</ref><ref name="pmid7962324">{{cite journal |vauthors=Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T |title=Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma |journal=J. Clin. Endocrinol. Metab. |volume=79 |issue=5 |pages=1322–7 |year=1994 |pmid=7962324 |doi=10.1210/jcem.79.5.7962324 |url=}}</ref><ref name="pmid12679445">{{cite journal |vauthors=Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF |title=Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1603–9 |year=2003 |pmid=12679445 |doi=10.1210/jc.2002-020773 |url=}}</ref> | ||
| style="background: #DCDCDC;" |Tumor cells secretes parathyroid hormone related protein (PTHrP) which has similar action as parathyroid hormone. | | style="background: #DCDCDC;" |Tumor cells secretes parathyroid hormone related protein (PTHrP) which has similar action as parathyroid hormone. | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
Line 140: | Line 140: | ||
* MRI | * MRI | ||
|- | |- | ||
| style="background: #F0FFFF; text-align: center;" |Ectopic parathyroid hormone | | style="background: #F0FFFF; text-align: center;" |Ectopic parathyroid hormone<ref name="pmid16263810">{{cite journal |vauthors=VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R |title=Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=2 |pages=580–3 |year=2006 |pmid=16263810 |doi=10.1210/jc.2005-2095 |url=}}</ref> | ||
| style="background: #DCDCDC;" |Some tumors leads to ectopic production of parathyroid hormone. | | style="background: #DCDCDC;" |Some tumors leads to ectopic production of parathyroid hormone. | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
Line 155: | Line 155: | ||
|- | |- | ||
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Medication induced''' | | rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Medication induced''' | ||
| style="background: #F0FFFF; text-align: center;" |Lithium | | style="background: #F0FFFF; text-align: center;" |Lithium<ref name="pmid2918061">{{cite journal |vauthors=Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S |title=Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume |journal=J. Clin. Endocrinol. Metab. |volume=68 |issue=3 |pages=654–60 |year=1989 |pmid=2918061 |doi=10.1210/jcem-68-3-654 |url=}}</ref> | ||
| style="background: #DCDCDC;" |Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement if parathyroid gland after weeks to months of therapy. | | style="background: #DCDCDC;" |Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement if parathyroid gland after weeks to months of therapy. | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
Line 194: | Line 194: | ||
* History of: | * History of: | ||
** Excess intake vitamin D | ** Excess intake vitamin D | ||
** Excess milk fortified with vitamin D | ** Excess milk fortified with vitamin D<ref name="pmid1313547">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref> | ||
** Topical application of vitamin D analogue analogue calcipotriol | ** Topical application of vitamin D analogue analogue calcipotriol<ref name="pmid8120527">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref> | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | | ||
* '''↑''' Calcium | * '''↑''' Calcium | ||
Line 202: | Line 202: | ||
|- | |- | ||
| style="background: #F0FFFF; text-align: center;" |'''Granulomatous disease''' | | style="background: #F0FFFF; text-align: center;" |'''Granulomatous disease''' | ||
| style="background: #F0FFFF; text-align: center;" |Sarcoidosis | | style="background: #F0FFFF; text-align: center;" |Sarcoidosis<ref name="pmid9215298">{{cite journal |vauthors=Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E |title=gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=7 |pages=2222–32 |year=1997 |pmid=9215298 |doi=10.1210/jcem.82.7.4074 |url=}}</ref> | ||
| style="background: #DCDCDC;" |Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages. | | style="background: #DCDCDC;" |Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages. | ||
| style="background: #DCDCDC;" | | | style="background: #DCDCDC;" | |
Revision as of 14:21, 8 September 2017
There are three types of hyperparathyroidism and should be differentiated between each other. Hyperparathyroidism should be differeniated from other causes of hypercalcemia. Causes of hypercalcemia include:
- Parathyroid related
- Primary hyperparathyroidism
- Typical primary hyperparathyroidism
- Familial hypocalciuric hypercalcemia
- Secondary hyperparathyroidism
- Tertiary hyperparathyroidism
- Primary hyperparathyroidism
- Non-parathyroid related
- Malignancy
- Para-neoplastic syndrome: Parathyroid hormone related peptide
- Hypercalcemia due to bone destruction
- Medication induced
- Thiazide diuretics
- Lithium
- Nutritional
- Milk alkali syndrome
- Vitamin D toxicity
- Granulomatous disease
- Sarcoidosis
- Surgical
- Immobilization
- Malignancy
Hypercalcemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Related to Parathyroid gland | Unrelated to parathyroid gland | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Primary hyperparathyroidism | Secondary hyperparathyroidism | Tertiary hyperparathyroidism | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Typical primary hyperparathyroidism | Familial hypocalciuric hypercalcemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Malignancy | Medication induced | Nutritional | Granulomatous disease | Surgical | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Para-neoplastic syndrome: Parathyroid hormone related peptide | Metaplasia: Hypercalcemia due to bone destruction | Thiazide diuretics | Lithium | Milk alkali syndrome | Vitamin D toxicity | Sarcoidosis | Immobilization | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Differential diagnosis
Differential diagnosis of hyperparathyroidism on the basis of hypercalcemia | |||||
---|---|---|---|---|---|
Disorder | Mechanism of hypercalcemia | Clinical features | Laboratory findings | Imaging & diagnostic modalities | |
Hyperparathyroidism | Primary hyperparathyroidism | Increase in secretion of parathyroid hormone (PTH) from a primary process in parathyroid gland. Parathyroid hormone causes increase in serum calcium. |
|
|
Findings of bone resorption:
Preoperative localization of hyperfunctioning parathyroid gland:
Predicting post-operative success:
|
Secondary hyperparathyroidism | Increase in secretion of parathyroid hormone (PTH) from a secondary process. Parathyroid hormone causes increase in serum calcium. |
|
| ||
Tertiary hyperparathyroidism | Continuous elevation of parathyroid hormone (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes increase in serum calcium. |
|
| ||
Malignancy[1] | Humoral hypercalcemia of malignancy[2][3][4] | Tumor cells secretes parathyroid hormone related protein (PTHrP) which has similar action as parathyroid hormone. |
|
|
|
Osteolytic tumors | Multiple myeloma produces osteolysis of bones causing hypercalcemia. Osteolytic metastasis can cause bone resorption causing hypercalcemia. |
|
|
| |
Production of calcitirol | Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia. |
|
|
| |
Ectopic parathyroid hormone[5] | Some tumors leads to ectopic production of parathyroid hormone. |
|
|
| |
Medication induced | Lithium[6] | Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement if parathyroid gland after weeks to months of therapy. |
|
|
|
Thiazide diuretics | Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia |
|
|
-- | |
Nutritional | Milk-alkali syndrome | Hypercalcemia is be caused by high intake of calcium carbonate |
|
|
|
Vitamin D toxicity | Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia. |
|
-- | ||
Granulomatous disease | Sarcoidosis[9] | Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages. |
|
|
|
- ↑ Mirrakhimov AE (2015). "Hypercalcemia of Malignancy: An Update on Pathogenesis and Management". N Am J Med Sci. 7 (11): 483–93. doi:10.4103/1947-2714.170600. PMC 4683803. PMID 26713296.
- ↑ Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG (1992). "Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia". Lancet. 339 (8786): 164–7. doi:10.1016/0140-6736(92)90220-W. PMID 1346019.
- ↑ Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T (1994). "Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma". J. Clin. Endocrinol. Metab. 79 (5): 1322–7. doi:10.1210/jcem.79.5.7962324. PMID 7962324.
- ↑ Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF (2003). "Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers". J. Clin. Endocrinol. Metab. 88 (4): 1603–9. doi:10.1210/jc.2002-020773. PMID 12679445.
- ↑ VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R (2006). "Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene". J. Clin. Endocrinol. Metab. 91 (2): 580–3. doi:10.1210/jc.2005-2095. PMID 16263810.
- ↑ Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S (1989). "Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume". J. Clin. Endocrinol. Metab. 68 (3): 654–60. doi:10.1210/jcem-68-3-654. PMID 2918061.
- ↑ Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
- ↑ Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
- ↑ Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E (1997). "gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses". J. Clin. Endocrinol. Metab. 82 (7): 2222–32. doi:10.1210/jcem.82.7.4074. PMID 9215298.